[go: up one dir, main page]

MX2007007187A - Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol. - Google Patents

Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.

Info

Publication number
MX2007007187A
MX2007007187A MX2007007187A MX2007007187A MX2007007187A MX 2007007187 A MX2007007187 A MX 2007007187A MX 2007007187 A MX2007007187 A MX 2007007187A MX 2007007187 A MX2007007187 A MX 2007007187A MX 2007007187 A MX2007007187 A MX 2007007187A
Authority
MX
Mexico
Prior art keywords
sup
derivatives
methyl
tetrahydroquinoline
trifluoromethylphenyl
Prior art date
Application number
MX2007007187A
Other languages
English (en)
Inventor
Carsten Schmeck
Hilmar Bischoff
Olaf Weber
Heike Gielen-Haertwig
Volkhart Li
Michael Thutewohl
Martina Wuttke
Alexandros Vakalopoulos
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35976678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007007187(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004061003A external-priority patent/DE102004061003A1/de
Priority claimed from DE102004060999A external-priority patent/DE102004060999A1/de
Priority claimed from DE102004061002A external-priority patent/DE102004061002A1/de
Priority claimed from DE102004060998A external-priority patent/DE102004060998A1/de
Priority claimed from DE102004061001A external-priority patent/DE102004061001A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MX2007007187A publication Critical patent/MX2007007187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a nuevos derivados de tetrahidroquinolina de formula (I), en la que R1 representa ciclohexilo o ciclopentilo, R2 y R3 representan respectivamente metilo o conjuntamente forman un ciclobutano, R4 representa ciclopropilo o isopropilo, asi como sus sales, solvatos y solvatos de las sales, a un procedimiento para su preparacion, a su uso solos o en combinaciones para el tratamiento y/o la prevencion de enfermedades, asi como a su uso para la preparacion de medicamentos, particularmente como inhibidores de la proteina de transferencia de ester de colesterol (CETP) para el tratamiento y/o la prevencion de enfermedades cardiovasculares, particularmente de hipolipoproteinemias, dislipidemias, hipertrigliceridemias, hiperlipidemias, hipercolesterolemias y arteriosclerosis.
MX2007007187A 2004-12-18 2005-12-10 Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol. MX2007007187A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE102004061003A DE102004061003A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060999A DE102004060999A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061002A DE102004061002A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060998A DE102004060998A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061001A DE102004061001A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
PCT/EP2005/013281 WO2006072362A1 (de) 2004-12-18 2005-12-10 (5s) - 3 - [(s)-fluor (4-trifluoromethylphenyl) methyl] -5,6,7,8-tetrahydrochinolin-5-ol derivative und ihre verwendung als cetp-inhibitoren

Publications (1)

Publication Number Publication Date
MX2007007187A true MX2007007187A (es) 2007-08-14

Family

ID=35976678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007187A MX2007007187A (es) 2004-12-18 2005-12-10 Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.

Country Status (9)

Country Link
US (1) US20080194609A1 (es)
EP (1) EP1828136A1 (es)
JP (1) JP2008524137A (es)
KR (1) KR20070090192A (es)
AU (1) AU2005324127A1 (es)
BR (1) BRPI0519566A2 (es)
CA (1) CA2591486A1 (es)
MX (1) MX2007007187A (es)
WO (1) WO2006072362A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1828137E (pt) * 2004-12-18 2012-07-04 Bayer Pharma AG Derivados de tetra-hidroquinolina substituídos com 4- cicloalquilo e sua utilização enquanto medicamentos
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR20100122089A (ko) * 2008-03-05 2010-11-19 베링거 인겔하임 인터내셔날 게엠베하 트리사이클릭 피리딘 유도체, 이러한 화합물을 함유하는 약제, 이들의 용도 및 제조방법
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EA201201160A1 (ru) 2010-02-19 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
RU2572606C2 (ru) 2010-07-09 2016-01-20 Дайити Санкио Компани, Лимитед Замещенное пиридиновое соединение
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013103150A1 (ja) 2012-01-06 2013-07-11 第一三共株式会社 置換ピリジン化合物の酸付加塩
JP6256469B2 (ja) 2012-08-03 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ［２．５］オクタン−５，７−ジオンの調製プロセス
WO2016037534A1 (en) 2014-09-09 2016-03-17 Boehringer Ingelheim International Trading (Shanghai) Co. Ltd. Novel process for preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE10148436A1 (de) * 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
PT1828137E (pt) * 2004-12-18 2012-07-04 Bayer Pharma AG Derivados de tetra-hidroquinolina substituídos com 4- cicloalquilo e sua utilização enquanto medicamentos

Also Published As

Publication number Publication date
AU2005324127A1 (en) 2006-07-13
BRPI0519566A2 (pt) 2009-01-27
CA2591486A1 (en) 2006-07-13
EP1828136A1 (de) 2007-09-05
US20080194609A1 (en) 2008-08-14
WO2006072362A1 (de) 2006-07-13
KR20070090192A (ko) 2007-09-05
JP2008524137A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
MX2007007187A (es) Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
IL217962A0 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
UA90269C2 (ru) Тетрагидрохинолиновые производные и способ их получения
GEP20094694B (en) Cetp inhibitors
AU4327600A (en) Aryl sulfonyls as factor xa inhibitors
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
PL371582A1 (en) Difluoromethyl thiazolyl carboxanilides
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
UA99626C2 (ru) Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина
IL183663A0 (en) Process for the preparation of a 2-ethylaminopyridine derivative
TNSN04255A1 (en) Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof.
GEP20022798B (en) Method For Producing 4-Carboxyamino-2-Substituted-1,2,3,4- Tetrahydroquinoline
NO20073146L (no) 4-cykloalkyl-substituerte tetrahydrokinolinderivater og deres anvendelse som medikamenter
TW200640913A (en) 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
GEP20022763B (en) 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor
ATE409693T1 (de) Verfahren zur herstellung von 2-(4- chlorbenzoylamino-3- 2(1h)-chinolinon-4-yl propionsäure
AU5558800A (en) Process for the production of 2-(2-pyridinylmethylsulphinyl)-1h-benzimidazoles
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
EP1231215A4 (en) PROCESS FOR PRODUCING ASPARTYLDIPEPTIDE ESTER DERIVATIVES, NOVEL MATCHING INTERMEDIATES AND PROCESS FOR PRODUCING SUCH INTERMEDIATES
TW200501952A (en) Pirfenidone gel formulations
MY130656A (en) Benzo [g] quinoline derivatives for treating glaucoma and myopia
ATE253565T1 (de) Inhibitoren der cholesterolesterase
ATE252566T1 (de) Herstellung von 2-(2-arylmorpholin-2- yl)ethanolderivaten und zwischenprodukte
AU2002321819A1 (en) Novel process for the production of pancreatic lipase inhibitor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal